OGENNYSEPharmaceutical PreparationsFiscal year ends December 31

ORAGENICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.42−0.01 (-2.97%)

Close on Oct 19, 2026

Market cap: $1.87M
P/E (TTM): –
Dividend yield: –

ORAGENICS INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	–	–	0.04	0.13	0.09	–	–	–	0	0	0	0.94	1.03	1.33	1.44	1.31
Cost of Revenue	–	–	–	–	–	–	–	–	0	0	0	0.37	0.34	0.88	0.71	0.91
Gross Profit	–	–	–	–	–	–	–	–	0	0	0	0.57	0.69	0.45	0.73	0.40
Research & Development	2.39	4.11	15	10	11	22	12	5.97	3.54	4.75	8.73	3.07	9.36	7.86	2.45	2.01
Selling, General & Admin	–	–	–	–	–	–	–	–	–	–	3.54	3.32	7.54	5.02	5.63	6.29
General & Administrative	6.97	6.44	5.45	4.48	5.27	4.53	3.76	4.02	3.18	3.79	3.05	–	–	–	–	–
Advertising Expenses	–	–	–	–	–	–	–	–	–	0.04	0.04	0.06	0.90	0.05	0.74	–
Operating Expenses	9.36	11	21	15	16	27	16	9.99	6.72	8.54	12	6.39	17	13	8.08	8.30
Operating Income	-9.36	-11	-21	-14	-16	-27	-16	-9.99	-6.72	-8.54	-12	-5.82	-16	-12	-7.35	-7.90
Interest Expense	0.79	0.03	0.03	0.02	0.02	0.01	0.01	0.01	0.22	0.00	0.08	0.00	0.02	0.66	0.33	0.03
Interest & Investment Income	0.18	0.05	0.21	0.14	0.08	0.09	0.32	0.09	0.01	0.04	0.02	0.04	0.02	0.02	0.00	0.00
Other Non-Operating Income	-0.62	-0.01	0.25	0.13	0.06	0.21	0.31	0.08	-0.01	0.05	-0.06	0.03	0.14	-0.66	-0.33	-0.64
Asset Impairment Charges	–	–	–	–	–	–	–	0	0	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	-0.03	0.01	–	–	–	–	–	0.00	0.00	0.00	–	–	–	–
Pretax Income	-9.98	-11	-21	-14	-16	-26	-16	-9.91	-6.73	-8.50	-12	-5.79	-16	-13	-7.68	-8.54
Income Tax Expense	-0.14	–	–	–	–	–	–	0	0	0	0	0	0	–	–	-0.73
Income from Continuing Operations	–	–	–	–	–	–	–	–	-6.73	-8.50	-12	–	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	1.48	0.13	–	–	–	–	–
Net Income	-9.84	-11	-21	-14	-16	-26	-16	-9.91	-6.73	-7.01	-12	-5.79	-16	-13	-7.68	-7.81
Preferred Dividends	–	–	–	–	–	–	–	1.41	–	–	–	–	–	–	–	–
Net Income to Common	–	–	–	–	–	–	-16	-11	-6.73	–	–	–	–	–	–	–
EPS (Basic)(per share)	-4.56	-47.88	-9.18	-7.11	-8.09	-27.26	-21.46	-50.46	-79.46	-91.06	-185.60	-92.80	-324.80	-429.20	-777.20	-823.60
EPS (Diluted)(per share)	-4.56	-47.88	-9.18	-7.11	-8.12	-27.26	-21.46	-50.46	-79.46	-91.06	-185.60	-92.80	-324.80	-429.20	-777.20	-823.60
Shares Outstanding (Basic, Weighted)(shares)	2.16	0.22	2.25	2.01	1.94	0.97	0.73	0.22	0.08	0.08	0.06	0.06	0.05	0.03	0.01	–
Shares Outstanding (Diluted, Weighted)(shares)	2.16	0.22	2.25	2.01	1.95	0.97	0.73	0.22	0.08	0.08	0.06	0.06	0.05	0.03	0.01	–
EBITDA	–	–	-21	-14	-16	-27	-16	-9.96	-6.65	-8.47	-12	-5.79	-16	-12	-7.27	-7.86

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -243.9%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.51
Dividend yield: –